MX344954B - Formulaciones de estilbeno fluorado adecuado para la formacion de imagenes pet. - Google Patents

Formulaciones de estilbeno fluorado adecuado para la formacion de imagenes pet.

Info

Publication number
MX344954B
MX344954B MX2013015074A MX2013015074A MX344954B MX 344954 B MX344954 B MX 344954B MX 2013015074 A MX2013015074 A MX 2013015074A MX 2013015074 A MX2013015074 A MX 2013015074A MX 344954 B MX344954 B MX 344954B
Authority
MX
Mexico
Prior art keywords
formulations
stilbene
pet imaging
fluorinated
fluorinated stilbene
Prior art date
Application number
MX2013015074A
Other languages
English (en)
Other versions
MX2013015074A (es
Inventor
Braun Rainer
Olbrich Carsten
Krause Michael
Burkhard Andreas
Richter Annett
Original Assignee
Piramal Imaging Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Imaging Sa filed Critical Piramal Imaging Sa
Publication of MX2013015074A publication Critical patent/MX2013015074A/es
Publication of MX344954B publication Critical patent/MX344954B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se dirige a formulaciones de ligando beta-amiloide lipofílico de estilbeno y más particularmente, a formulaciones que son capaces de administrarse parenteralmente, por ejemplo, intravenosamente, en donde el ligando beta amiloide lipofílico de estilbeno es un estilbeno fluorado. Además, la invención se dirige a un método para filtración estéril de formulaciones adecuadas para la formación de imágenes PET de mamíferos de acuerdo con la invención.
MX2013015074A 2011-06-21 2012-06-21 Formulaciones de estilbeno fluorado adecuado para la formacion de imagenes pet. MX344954B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11005047 2011-06-21
PCT/EP2012/062034 WO2012175641A1 (en) 2011-06-21 2012-06-21 Formulations of fluorinated stilbene suitable for pet imaging

Publications (2)

Publication Number Publication Date
MX2013015074A MX2013015074A (es) 2014-11-10
MX344954B true MX344954B (es) 2017-01-12

Family

ID=46354330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015074A MX344954B (es) 2011-06-21 2012-06-21 Formulaciones de estilbeno fluorado adecuado para la formacion de imagenes pet.

Country Status (21)

Country Link
US (1) US9308284B2 (es)
EP (1) EP2723394B1 (es)
JP (1) JP6081997B2 (es)
KR (1) KR101869129B1 (es)
CN (2) CN105833303A (es)
AU (1) AU2012274076B2 (es)
BR (1) BR112013032610B1 (es)
CA (1) CA2839961C (es)
DK (1) DK2723394T3 (es)
ES (1) ES2683818T3 (es)
HK (2) HK1197031A1 (es)
HR (1) HRP20181081T1 (es)
HU (1) HUE039909T2 (es)
IL (1) IL230042A (es)
MX (1) MX344954B (es)
MY (1) MY183997A (es)
PL (1) PL2723394T3 (es)
PT (1) PT2723394T (es)
RU (1) RU2623867C2 (es)
SI (1) SI2723394T1 (es)
WO (1) WO2012175641A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6207588B2 (ja) 2012-04-10 2017-10-04 ランセウス メディカル イメージング， インコーポレイテッド 放射性薬剤合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26102A (id) * 1998-02-20 2000-11-23 Ciba Sc Holding Ag Proses pembuatan senyawa-senyawa stilbena
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP4436928B2 (ja) 2001-08-27 2010-03-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用
SI2213652T1 (sl) * 2004-12-17 2015-03-31 The Trustees Of The University Of Pennsylvania Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
EA023014B1 (ru) * 2008-12-31 2016-04-29 Эвид Рэйдиофармасьютикалз, Инк. Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции
US8658129B2 (en) * 2009-06-04 2014-02-25 General Electric Company Agents and methods for the imaging of myelin basic protein
KR101718164B1 (ko) * 2009-12-17 2017-03-20 엘지전자 주식회사 인증 절차를 고려한 핸드오버 수행 방법 및 장치
EP2515948A1 (en) * 2009-12-23 2012-10-31 Piramal Imaging SA Formulations suitable for pet imaging with hydrophobic pet agents
BR112012030935B1 (pt) 2010-04-06 2020-11-17 Life Molecular Imaging Sa método para a produção de ligantes de beta-amiloide marcados com f-18

Also Published As

Publication number Publication date
EP2723394B1 (en) 2018-05-23
CN103841994A (zh) 2014-06-04
IL230042A (en) 2017-06-29
MX2013015074A (es) 2014-11-10
BR112013032610A2 (pt) 2017-01-24
BR112013032610B1 (pt) 2022-05-31
ES2683818T3 (es) 2018-09-28
CA2839961A1 (en) 2012-12-27
JP2014517054A (ja) 2014-07-17
US9308284B2 (en) 2016-04-12
JP6081997B2 (ja) 2017-02-15
RU2014101557A (ru) 2015-07-27
CN103841994B (zh) 2016-05-11
RU2623867C2 (ru) 2017-06-29
SI2723394T1 (sl) 2018-10-30
HUE039909T2 (hu) 2019-02-28
DK2723394T3 (en) 2018-08-13
MY183997A (en) 2021-03-17
NZ618977A (en) 2015-07-31
KR101869129B1 (ko) 2018-06-19
KR20140061347A (ko) 2014-05-21
HRP20181081T1 (hr) 2018-09-21
EP2723394A1 (en) 2014-04-30
PL2723394T3 (pl) 2018-11-30
WO2012175641A1 (en) 2012-12-27
HK1197031A1 (zh) 2015-01-02
CN105833303A (zh) 2016-08-10
CA2839961C (en) 2019-08-13
PT2723394T (pt) 2018-07-30
AU2012274076B2 (en) 2017-06-15
US20140241986A1 (en) 2014-08-28
HK1225648A1 (zh) 2017-09-15
AU2012274076A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
EP2713867A4 (en) MAGNETIC ZEPHALOGRAPHY SOURCE IMAGING
ZA201403795B (en) Formulations for the treatment of diabetes
EP2945662A4 (en) MOTOR FAILURE MONITOR FOR IMPLANTABLE BLOOD PUMP
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
IL231835A0 (en) Pyrrolopyrimidine compounds for cancer treatment
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
PH12014502032A1 (en) Treatment of brain cancer
IT1403684B1 (it) Macchina per la preparazione di bevande mediante infusione.
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
PL394332A1 (pl) Sposób wyznaczania elektronowych czasów relaksacji T₁ w tomografii EPR
EP2864906A4 (en) SEARCH FOR EVENTS BY PRESENT
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
GB201112359D0 (en) Filter for tomographic reconstruction
EA201200940A1 (ru) Композиции, приемлемые для рет-визуализации при помощи гидрофобных рет-агентов
EP2792361A4 (en) MEDICAL COMPOSITION FOR PREVENTING OR TREATING STATES OR DISEASES ASSOCIATED WITH AMYLOID BETA PEPTIDE
EP2910634A4 (en) VACCINE FOR THE PREVENTION OF SWINE DISEASE
GB201602989D0 (en) Wear rings for electric submersible pump stages
ZA201404191B (en) Solubilized magnolol analogs
MX344954B (es) Formulaciones de estilbeno fluorado adecuado para la formacion de imagenes pet.
UY34277A (es) Metodo para la eliminación del naftaleno
ZA201501515B (en) Imaging assembly for scanner
MX2015005992A (es) Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
GB201106260D0 (en) Forced induction for i.c. engines

Legal Events

Date Code Title Description
FG Grant or registration